On May 3, 2018, a Dentons China team successfully assisted Wuhan Easy Diagnosis Biomedicine Co., Ltd. ("Easy Diagnosis") in passing the IPO review.
The team was mainly composed of senior partner Fang Wang (Wuhan), partner Sherry Li (Beijing), paralegal Ping Kang, and Yue Li. They provided high-quality and efficient advice on all aspects of the deal, including due diligence, reorganization, standardization, counseling and filing, NEEQ delisting, feedback, and IPO application, successfully resolving a lot of problems for NEEQ-listed companies to get listed on the A-share market.
Established in 2008, Easy Diagnosis is a leading IVD manufacturer, specializing in research & development, production and sales of POCT rapid diagnosis reagents and related equipment. The company plans to get listed on the Shenzhen Stock Exchange SME Board market to raise RMB430 million. The funds raised will be used in IVD production expansion, mobile medical product development, R&D center construction and marketing network establishment, with an aim to further consolidate the company's leading position in the field of biomedicine.